Currently, there are 78.23M common shares owned by the public and among those 76.93M shares have been available to trade.
The company’s stock has a 5-day price change of 28.08% and -1.60% over the past three months. CTMX shares are trading -20.65% year to date (YTD), with the 12-month market performance down to -12.77% lower. It has a 12-month low price of $0.83 and touched a high of $5.85 over the same period. CTMX has an average intraday trading volume of 845.16K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 23.96%, 15.31%, and -21.92% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of CytomX Therapeutics Inc (NASDAQ: CTMX) shares accounts for 65.49% of the company’s 78.23M shares outstanding.
It has a market capitalization of $96.26M and a beta (3y monthly) value of 1.03. The stock’s trailing 12-month PE ratio is 7.25, while the earnings-per-share (ttm) stands at $0.17. Price movements for the stock have been influenced by the stock’s volatility, which stands at 9.68% over the week and 8.19% over the month.
Earnings per share for the fiscal year are expected to decrease by -328.04%, and -908.36% over the next financial year. EPS should shrink at an annualized rate of -0.90% over the next five years, compared to 67.21% over the past 5-year period.
Looking at the support for the CTMX, a number of firms have released research notes about the stock. Piper Sandler stated their Overweight rating for the stock in a research note on May 28, 2024, with the firm’s price target at $2.25-$3.50. Wedbush coverage for the CytomX Therapeutics Inc (CTMX) stock in a research note released on May 09, 2024 offered a Outperform rating with a price target of $8. BMO Capital Markets on their part issued Market Perform rating on November 14, 2022.
